Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

Tundra lists 1 Acute Myeloid Leukemia With T(8;21)(Q22;Q22) clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07028073

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

The goal of this clinical trial is to learn if avapritinib combined with standard induction therapy works to treat newly diagnosed adult acute myeloid leukemia (AML) patients with KIT mutations and t(8;21)(q22;q22.1); inv(16)(p13.1q22) or t(16;16)(p13.1;q22). It will also investigate the safety and tolerability of this combination therapy. The main questions it aims to answer are: To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of avapritinib combined with chemotherapy by Dose-limiting toxicity (DLT). Does this combination therapy improve the rates of minimal residual disease (MRD) negativity and long-term survival outcomes?

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-19

1 state

Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

Acute Myeloid Leukemia With T(16;16)(P13;Q22)

KIT Gene Mutation